News coverage about Karyopharm Therapeutics (NASDAQ:KPTI) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.8767856844987 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Karyopharm Therapeutics (NASDAQ KPTI) traded down $0.74 during midday trading on Wednesday, reaching $10.04. 333,400 shares of the company traded hands, compared to its average volume of 200,470. Karyopharm Therapeutics has a 52-week low of $7.48 and a 52-week high of $14.63. The stock has a market capitalization of $475.11, a price-to-earnings ratio of -3.77 and a beta of 4.08.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities analysts expect that Karyopharm Therapeutics will post -2.58 EPS for the current year.

Several research analysts recently commented on KPTI shares. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. BidaskClub lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. started coverage on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target on the stock. Royal Bank of Canada restated a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.33.

In other news, SVP Christopher Brett Primiano sold 27,042 shares of Karyopharm Therapeutics stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total transaction of $277,991.76. Following the sale, the senior vice president now owns 11,381 shares in the company, valued at $116,996.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $10.39, for a total transaction of $103,900.00. The disclosure for this sale can be found here. Insiders have sold 62,000 shares of company stock worth $630,069 in the last quarter. Insiders own 14.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Karyopharm Therapeutics (KPTI) Stock Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/17/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-karyopharm-therapeutics-kpti-stock-price.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.